SPX3,585.62-54.85 -1.51%
DIA287.30-4.91 -1.68%
IXIC10,575.62-161.89 -1.51%

BRIEF-NGM Bio Presents Updated Preliminary Findings From The Ongoing Phase 1B Dose Escalation Trial Of NGM120

BRIEF-NGM Bio Presents Updated Preliminary Findings From The Ongoing Phase 1B Dose Escalation Trial Of NGM120

Reuters · 09/13/2022 17:36
BRIEF-NGM Bio Presents Updated Preliminary Findings From The Ongoing Phase 1B Dose Escalation Trial Of NGM120

- NGM Biopharmaceuticals Inc NGM.O:

  • NGM BIO PRESENTS UPDATED PRELIMINARY FINDINGS FROM THE ONGOING PHASE 1B DOSE ESCALATION TRIAL OF NGM120 IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH METASTATIC PANCREATIC CANCER AT AACR SPECIAL CONFERENCE: PANCREATIC CANCER

  • NGM BIOPHARMACEUTICALS INC- NGM120 HAS BEEN WELL TOLERATED TO DATE IN PATIENTS IN PHASE 1B COMBINATION COHORT WITH NO DOSE-LIMITING TOXICITIES

Source text for Eikon: ID:

Further company coverage: NGM.O


((Reuters.Briefs@thomsonreuters.com;))